Proteolysis-targeting chimeras (PROTACs) are a class of bifunctional molecules which are enabling the development of drugs against targets once considered inaccessible. PROTACs bring a protein of interest into close-proximity to an E3 ubiquitin ligase, resulting in the degradation of the target protein by the ubiquitin-proteasome system. Due to the complex mechanism of action of PROTACs, developing a clear understanding of structure-activity relationships can be quite challenging.
This webinar will focus on PROTAC biology workflows, such as in vitro screening assays, in vivo testing, and optimization of DMPK properties. Topics will include the best use of biochemical assays to measure binary/ternary complex formation, cell-based assays to assess target engagement and degradation, strategies for enhancing drug delivery and formulation, and PK/PD evaluation of PROTACs in animal models.
Key Learning Objectives:
PROTAC biology workflows, including in vitro screening assays, in vivo testing, and optimization of DMPK properties
Strategies for enhancing drug delivery and formulation
PK/PD evaluation of PROTACs in animal models
Who Should Attend:
Scientists and researchers interested in protein degradation workflows
Brought to you by:
Kris Rutten Director, WuXi AppTec
Lingbing Sun Director, Biophysics, WuXi AppTec
Dr. Liping Ma Senior Study Director, WuXi AppTec
Liang Mao Senior Director, WuXi STA, a WuXi AppTec Company